<DOC>
	<DOC>NCT01103622</DOC>
	<brief_summary>The purpose of this study is to determine whether AZD1656 will affect the pharmacokinetics (PK) of digoxin in type 2 diabetes mellitus (T2DM) patients.</brief_summary>
	<brief_title>Investigate the Effect of AZD1656 on the Pharmacokinetics of Digoxin in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<criteria>Patients with confirmed type 2 diabetes for at least 1 year and treated with metformin as a single treatment or in combination with one other oral anti diabetic for at least 2 months prior to screening. Body mass index between ≥19 and ≤42 kg/m2. Haemoglobin (Hb) A1c ≥6.5% and ≤9.5% at enrolment. History of cardiovascular disease, eg, left ventricular hypertrophy, uncontrolled hypertension, paroxysmal or persistent cardiac arrhythmia or ischemic heart disease. Systolic blood pressure &gt;160 mmHg or diastolic blood pressure &gt;95 mmHg at screening Use of amiodarone within 3 months prior to screening and the use of potent CYP450 inhibitors</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Type 2</keyword>
	<keyword>Digoxin</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>